摘要
HIV耐药会影响抗病毒治疗的长期疗效,使得艾滋病流行结束于2030年的目标难以实现。不同国家采用不同策略来预防和评估HIV耐药的产生和传播。目前,高收入国家对HIV感染者进行个体耐药检测。多数中低收入国家采用WHO提出的群体监测策略,监测耐药早期预警指标,评估治疗人群获得性耐药,监测治疗前耐药、传播性耐药及18月龄以下儿童耐药等措施。我国采用HIV耐药个体检测和群体监测相结合的防控策略。
HIV drug resistance （HIVDR） can threat the long-term effects of antiretroviral therapy （ART）, and jeopardize the goal of eliminating HIV in 2030. Different strategies are adopted in different countries to prevent and assess the emergence and transmission of HIVDR. In high income countries, the HIVDR testing for individual with HIV is used at present. In most of middle- and low- income countries, population level strategies are recommended, including monitoring of HIVDR early warning indicators, surveillance of acquired drug resistance in populations receiving ART, surveillance of pretreatment drug resistance, surveillance of transmitted drug resistances, and surveillance of HIVDR among treatment-naive infant less than 18 months of age. The combination of individual HIVDR testing and population-level surveys are taken as the prevention strategy in China.
出处
《传染病信息》
2017年第6期351-354,共4页
Infectious Disease Information
基金
中美艾滋病合作项目(2017-2018-7.12)
关键词
HIV
耐药
抗病毒治疗
评估
HIV
drug resistance
antiretroviral therapy
assessment
